Andrew Koven

Andrew Ian Koven is currently Chairman at MetaVia, Inc. since 2022, with employment at the firm starting in 2021.
Former roles include President, Director & Chief Administrative Officer at Neurologix, Inc. in 2011; Lead Independent Director at Kala Bio, Inc. from 2018 to 2026; Secretary, Executive VP & General Counsel at Sumitomo Pharma America, Inc. from 2007 to 2010; Associate General Counsel at Warner-Lambert Co. from 1993 to 2000; Secretary, Executive VP & General Counsel at KOS Pharmaceuticals, Inc. from 2003 to 2006; Chief Administrative & Legal Officer, Executive VP at Inspire Pharmaceuticals, Inc. from 2010 to 2011; President & Chief Business Officer at POZEN, Inc. from 2015 to 2016; Secretary, CAO, Executive VP & General Counsel at Auxilium Pharmaceuticals LLC from 2012 to 2015; Associate at Cahill Gordon & Reindel LLP from 1986 to 1992; Senior Vice President & General Counsel at Lavipharm Corp.
from 2000 to 2003; Counsel-Corporate & Investment Division at Equitable Financial Life Insurance Co. from 1992 to 1993; Secretary, Senior Vice President & General Counsel at Lavipharm Laboratories, Inc. from 2000 to 2003; President & Chief Business Officer at Old API Wind-down Ltd. from 2015 to 2019; and President & Chief Business Officer at Aralez Pharmaceuticals Plc.
Education includes undergraduate and graduate degrees from Dalhousie University conferred in 1978 and 1981, respectively, and a graduate degree from Columbia Law School.